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We used the updated nation-wide Swedish Family-Cancer Database to examine familial risks in data from 1961 to 1998 on 1252
invasive and 2474 in situ squamous cell carcinoma (SCC) of the skin among offspring, and over 10 times more among parents. In 259
families a parent and an offspring had skin SCC. The familial standardised incidence ratios (SIRs) were 2.72 for invasive and 2.40 for in
situ skin cancers in offspring. Multiple skin cancers in parents were associated with increased SIRs for invasive SCC in offspring, being
2.55 for one and up to 14.93 for two invasive and two in situ cancers in parents; the corresponding in situ SCC risks were 2.28 and
7.49. The population attributable fraction for any familial skin SCC, invasive or in situ, was 4.1%. Melanoma was the only discordant
tumour that was associated with invasive and in situ skin SCC. These results provide evidence that there is an underlying hereditary
susceptibility for at least a part of the familial clustering for skin SCC.
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Squamous cell carcinoma (SCC) of the skin is not recorded by
most cancer registries and its established risk factors are limited to
fair skin, ultraviolet light, arsenic compounds and immunosup-
pression, while less is known about benign lesions, such as actinic
keratosis and in situ carcinoma (intraepidermal SCC, or Bowen’s
disease) (IARC, 1990, 1995; English et al, 1997) The Swedish
Cancer Registry has recorded both invasive and in situ SCC whose
incidence has rapidly increased over the past 20 years (Center for
Epidemiology, 2000; Wassberg et al, 2001). Skin SCC is the fourth
most common cancer in men and women in Sweden in 1998, and
the in situ form is the most common benign/precancerous tumour
in men and the second among women after in situ cervical cancer.
In situ skin cancer does not appear to be a simple precursor lesion
to invasive SCC because the age of onset of the two forms is
similar; a true precursor lesion would be expected to show an
earlier age of onset, as with cervical in situ and invasive cancers
(MacKie, 1996; Reese, 1998, 2002; Hemminki et al, 1999; Heaphy
and Ackerman, 2000; Hemminki and Dong, 2000c; Rees, 2002).
We have previously reported on familial skin cancer from the
nation-wide Swedish Family-Cancer Database (Hemminki and
Dong, 2000a). In comparisons of familial cancers at many sites in
the Database, the standardised incidence ratio (SIR) for invasive
skin cancer (2.4) was intermediate, but, it exceeded that for breast
(SIR 1.85) and colon (1.89) cancers (Dong and Hemminki, 2001a).
We have used the most recent update of the nation-wide Swedish
Family-Cancer Database, covering 10.2 million individuals and
over 1.0 million tumours to investigate familial relations of
invasive and in situ SCC. Association of skin SCC with other
cancers in families is also described. In contrast to our previous
study, the number of cases has almost doubled in the offspring
generation, allowing separate analyses for familial risks by invasive
and in situ SCC, as well as by multiple skin tumours.
SUBJECTS AND METHODS
The subjects were identified from the Family-Cancer Database,
where the first generation (parents) was regarded as probands and
familial risks were calculated for the second generation (offspring).
We analysed the risk of invasive and in situ SCC in offspring by the
same or discordant cancer in parents.
The Swedish Family-Cancer Database
The Swedish Family-Cancer Database, updated in 2000, includes
persons born in Sweden after 1931 with their biological parents,
totalling over 10.2 million individuals and organised in 3.2 million
families (Hemminki et al, 1998; Hemminki and Vaittinen, 1998b).
Cancers, including in situ skin cancers (‘precancerous epithelial
lesions’), were retrieved from the nation-wide Swedish Cancer
Registry from years 1961 to 1998. The completeness of cancer
registration in the 1970s has been estimated to be over 95%, and is
now considered to be close to 100%. The percentage of
cytologically or histologically verified cases of cancer has been
close to 100% (Center for Epidemiology, 2000).
A four-digit diagnostic code based on the seventh revision of the
ICD-7 has been used since 1958, together with a code for
histological type (WHO/HS/CANC/24.1 Histology Code) in broad
subgroups, such as adenocarcinoma and SCC, and we refer to this
as the ‘PAD code’, for pathologic anatomic diagnosis. From year
1993 onwards ICD-O-2/ICD with histopathological data according
to the Systematised Nomenclature of Medicine (SNOMED, http://
snomed.org) was used which we refer to as ‘SNOMED’. Only the
first invasive skin cancer or in situ cancer was considered, if not
stated otherwise. Among discordant cancers in parents, the
following ICD-7 codes were pooled: 140 (lip), 141 (tongue), 143–
148 (mouth, pharynx) and 161 (larynx), and ‘leukaemia’ 204–207
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y(leukaemias), 208 (polycytemia vera) and 209 (myelofibrosis).
Only adenocarcinoma was included for colorectum and only
melanomo for eye cancer.
Statistical analysis
Family history information was collected on all first-degree
relatives (parents, siblings and children) but only the parent–
offspring relationship was used here because of the small numbers
of affected sibling pairs. There were only one sibling pair with
invasive SCC and four pairs with in situ SCC and these were
included separately in the analysis of familial risk. Standardised
incidence ratios, calculated as the ratio of observed (O) to expected
(E) number of cases, were used to measure the cancer risks for
offspring by occurrence of cancers in their parents. The expected
numbers of cancers were obtained by assuming that these persons
had the same incidence as in the corresponding general population
in the Database: offspring were included if their first primary
cancer was diagnised at ages 0–66 years, but no limit was placed
on the age of parents. Tumor site-, sex-, 5-year-age- and 10-year-
period-specific rates were applied to the relevant person-years at
risk (Esteve et al, 1994). Person-years at risk were accumulated for
each offspring beginning with the date of birth or January 1, 1961
and ending with the date of diagnosis of a first primary cancer,
date of death, date of emigration, or December 31, 1998 whichever
was earliest. Confidence intervals (95% CI) were calculated
assuming that the numbers of cancer cases among offspring
follow a Poisson distribution (Esteve et al, 1994). The population
attributable fraction (PAF) of cases with a family history of
invasive or in situ skin cancer was estimated as follows: proportion
of cases with a family history(familial SIR1)/familial SIR, as
defined by Miettinen (1974) and cited as formulas (16)–(21) by
Rothman and Greenland (1998).
RESULTS
Table 1 presents details from the Family-Cancer Database of 1252
invasive skin SCCs in offspring and 17054 in parents, together
with 2474 and 26999, respectively of in situ SCCs. Age-
standardised incidence of invasive and in situ SCC is shown in
Figure 1 for men and women. Male rates are almost two times
higher for invasive cancer, but for in situ cancer there is no
difference between the genders. The dramatic increase is seen for
all rates, and particularly for in situ cancer, the incidence of which
exceeds that of invasive SCC at the end of the study period.
Table 2 shows SIRs of 2.72 (95% CI 2.01–3.61) for offspring
invasive SCC when parents had invasive skin cancer, and 2.24
(1.69–2.92) when they had in situ SCC by the PAD code.
According to the SNOMED code, the corresponding SIRs were
3.35 (2.33–4.66) and 2.90 (2.09–3.93), respectively. The SIRs for
offspring in situ SCCs were 2.38 (1.89–2.95) and 2.40 (1.98–2.88)
when parents had invasive and in situ cancer, respectively. For the
mixed type of in situ cancer (basal cell and SCC) when parents had
in situ SCC, the SIR was 3.47 (1.72–6.23), which was the highest
Table 1 Numbers of skin cancer by histopathological type
Number in offspring Number in parents
Cancer type
a Son Daughter Offspring Father Mother Parents
Invasive SSC 728 524 1252 10945 6109 17054
Invasive SSC (SNOMED) 513 346 859 4887 3272 8159
In situ SCC 1248 1226 2474 13397 13602 26999
Mixed type 88 77 165 849 544 1393
Actinic keratosis (SNOMED) 63 72 135 3979 4116 8095
In situ SCC (SNOMED) 483 415 898 619 741 1360
Bowen’s disease (SNOMED) 257 289 546 1588 1849 3437
aFollow-up for SNOMED, 1993–1998.
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Figure 1 Age-standardised incidence rate of invasive and in situ SCC for
the period 1961–1998 (standardised according to European standard
population)
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groups of in situ cancers, actinic keratosis, in situ SCC and
Bowen’s disease with SIRs between 2.14 (1.22–3.49) and 2.78
(1.86–3.99). Among a total of 1252 offspring with invasive skin
SCC, 48 (3.8%) had an affected parent and using this proportion
and the familial SIR of 2.72, the PAF for familial risk was 2.4%.
Similarly, 116 of 2474 (4.7%) offspring with in situ tumour had a
parent with in situ SCC and using 2.40 for the familial SIR, the PAF
for in situ familial SCC was 2.7%.
When invasive and in situ skin SCC were considered together
(Table 3), 259 of 3586 (7.2%) offspring with SCC had parents with
SCC, resulting in an SIR of 2.29 (95% CI 2.02–2.59) and a PAF of
4.1%. In Table 3, age-specific data for familial skin SCC are also
shown. The highest risk was noted at an early age of 20–29 years
with SIR of 3.32 (1.05–7.81), while at later ages the SIRs were
between 1.92 (1.07–3.17) and 2.36 (1.97–2.80).
Multiple skin cancers in parents, including invasive and in situ
SCC skin cancers (Table 4), conveyed an increased SIR to offspring
when compared to those of parents with a single skin cancer. The
SIR was 14.93 (2.82–44.20) for offspring invasive SCC when a
parent had two invasive and two in situ cancers, the comparable in
situ SCC risk was 7.49 (1.41–22.18). However, the number of
affected offspring was small when parents had multiple skin
cancers.
Familial risks of SCC in offspring were analysed when parents
had diverse invasive cancers (Table 5). Among the parental sites,
the urinary bladder, prostate, skin melanoma, skin SCC and eye
melanoma were associated with invasive SCC in offspring. For
offspring in situ SCC, only parental melanoma and invasive SCC
increased the risk. The data in Table 5 were derived from 46
comparisons among cancer sites, which could have resulted in 2 or
3 significant findings owing to chance alone. We found nine
significant differences, of which seven were increases, suggesting
that some increases were genuine.
DISCUSSION
The only previous study of familial skin SCC is that by Hemminki
and Dong (2000a). Our present study is substantially larger,
allowing analysis of both offspring and parents by the squamous
cell histology. Some possible biases need to be considered. The
quality of the Swedish Cancer Registry is high, but the marked
increas particularly of in situ cases (Figure 1) raises the possibility
that reporting to the Registry has improved over the time. All
registered cases of SCC were verified by histology or cytology
(Center for Epidemiology, 2000). At present there may be an
increased concern and alertness in families with affected
individuals and may be seeking medical opinion about treatment
more often than in the past. This cannot be excluded in Sweden for
SCC but as the diagnoses are always confirmed by histology or
cytology, the effect would be a lead-time bias rather than a false
diagnosis (Hemminki and Vaittinen, 1998a; Wassberg et al, 1999).
The numbers of affected types of families argue against bias: as
compared to 259 affected parent–offspring families with any skin
SCC, there was only one sibling pair with invasive SCC and four
pairs with in situ SCC. Considering the number of skin tumours in
the 3.2 million families of the Database, the number of affected
sibling pairs was within expectations.
The data on family clustering of skin SCC show a strong effect
with a SIR of 3.35 for concordant invasive SCC in parents and
offspring, based on the SNOMED codes used during 1993–1998
although the corresponding risk for the whole period, 1961–1998,
was somewhat lower at 2.72. These risks, together with the very
high SIRs from multiple tumours in the parental probands, such as
7.25 from three tumours and 14.93 from four tumours provide
strong evidence for heritable effects in skin SCC. The familial SIRs
for in situ SCC were also increased but tended to be lower than
those for invasive tumours, which could imply a degree of
diagnostic inconsistency. Both invasive and in situ form were
represented in the same families giving further evidence of their
biological similarity. The mixed in situ tumour with basal and
squamous cell elements showed the highest SIR of all comparisons,
3.47 from parental in situ SCC. The three types of in situ tumours,
in the SNOMED classification were comparable in their familial
presentation, as far as the number of cases allowed any
conclusions. In the dermatological literature there has been a long
standing controversy as to the distinction of the different kinds of
in situ tumours and whether they represent different biological
entities between each other and between them and invasive forms
(MacKie, 1996; Heaphy and Ackerman, 2000; Rees, 2002).
When invasive and in situ skin cancer were considered together,
familial risk was higher at young ages and the PAF of familial SCC
was 4.1%. Familial clustering may be because of inherited and/or
environmental factors. One way to assess the shared environ-
Table 2 Standardised incidence ratio for SCC in offspring of parents with skin cancer
SCC in parent In situ SCC in parent
Skin cancer in offspring
a O SIR 95% CI O SIR 95% CI
Invasive SSC 48 2.72 2.01 3.61 55 2.24 1.69 2.92
Invasive SSC (SNOMED) 35 3.35 2.33 4.66 42 2.90 2.09 3.93
In situ SCC 83 2.38 1.89 2.95 116 2.4 1.98 2.88
In situ SCC (SNOMED) 29 2.78 1.86 3.99 35 2.44 1.70 3.39
Mixed type 2 0.88 0.08 3.25 11 3.47 1.72 6.23
Actinic keratosis (SNOMED) 5 2.51 0.79 5.90 7 2.60 1.03 5.38
Bowen’s disease (SNOMED) 16 2.14 1.22 3.49 23 2.21 1.40 3.33
aFollow-up for SNOMED, 1993–1998. Bold type: 95% CI does not include 1.00. O, observed; SIR, standardised incidence
rate.
Table 3 Standardised incidence ratio for SCC in offspring of parents
with skin cancer
Age group (y) O SIR 95% CI
20–29 5 3.32 1.05 7.81
30–39 15 1.92 1.07 3.17
40–49 71 2.31 1.81 2.92
50–59 131 2.36 1.97 2.80
60–66 37 2.15 1.52 2.97
All 259 2.29 2.02 2.59
Bold type: 95% CI does not include 1.00. O, observed; SIR, standardised incidence
rate.
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correlation of skin SCC between spouses and the fact that no such
correlation has been found in this Database and this comparison
suggests that heritable factors are more important than environ-
mental factors in the familial aggregation of skin cancer
(Hemminki et al, 2001a; Hemminki and Jiang, 2002). Moreover,
in a separate study we have found that familial risk can be found
both in sun-exposed and covered sites, adding to the evidence that
sun exposure alone does not explain the familial aggregation
(unpublished data). The molecular basis of SCC is not fully
understood (Reese, 1998, 2002; Rees, 2002), mutations in the PTC
gene, common in basal cell carcinoma, being rare in SCC.
Although p53 and H-ras mutations are common they may not be
the initial events in skin carcinogenesis. Squamous cell carcinoma
is not a feature of Li-Fraumeni families who have a germ-line
mutation in the p53 gene (Malkin, 1998). Since sun exposure is an
established risk factor of skin cancer, at least part of the familial
risk may be explained by cumulative exposure to sun, or by an
inherited trait of skin type. SCC is a major complication in two
rare recessive syndromes: xeroderma pigmentosum and Bloom
syndrome, involving defects in DNA excision repair and DNA
helicase, respectively (German and Ellis, 1998; Balajee and Bohr,
2000; de Boer and Hoeijmakers, 2000). Since these syndromes are
recessive, they would not be observed when comparing familial
cancers between parents and offspring. The important question of
a possible cancer risk in the heterozygous carriers in the DNA
repair gene defects awaits further study.
Melanoma was the only discordant tumour that associated with
invasive and in situ skin SCC, an association also noted in
melanoma families (Hemminki et al, 2001b). In the present study,
the excess familial risks for invasive and in situ SCC in offspring
were 2.2 and 2.6 times higher, respectively, when a parent had the
Table 4 Standardised incidence ratio for SCC in offspring of parents with skin cancers
SCC in offspring In situ SCC in offspring
Parental SCC O SIR 95% CI O SIR 95% CI
1 invasive 42 2.55 1.84 3.45 71 2.18 1.70 2.74
1 in situ 46 2.14 1.56 2.85 97 2.28 1.85 2.78
1 invasive and 1 in situ 3 1.83 0.34 5.41 9 2.77 1.26 5.28
2 invasive 6 4.09 1.47 8.96 12 4.10 2.11 7.19
2 in situ 9 2.99 1.36 5.70 18 3.02 1.78 4.78
2 invasive and 1 in situ 4 7.25 1.89 18.74 6 5.43 1.96 11.90
1 invasive and 2 in situ 3 4.29 0.81 12.69 6 4.30 1.55 9.42
2 invasive and 2 in situ 3 14.93 2.82 44.2 3 7.49 1.41 22.18
Bold type: 95% CI does not include 1.00. O, observed; SIR, standardised incidence rate.
Table 5 Standardised incidence ratio for SCC in offspring by type of parental cancer
a
SCC in offspring In situ SCC in offspring
Parental invasive O SIR 95% CI O SIR 95% CI
Upper aerodiagestive tract 16 1.13 0.64 1.84 21 0.70 0.44 1.08
Oesophagus 7 1.38 0.55 2.87 6 0.56 0.20 1.23
Stomach 28 0.77 0.51 1.11 66 0.85 0.66 1.08
Colon 77 1.13 0.89 1.41 118 0.82 0.68 0.99
Liver 14 0.66 0.36 1.12 26 0.58 0.38 0.86
Pancreas 23 1.11 0.70 1.67 34 0.78 0.54 1.09
Lung 46 1.11 0.81 1.48 85 0.99 0.79 1.22
Breast 60 0.99 0.76 1.28 110 0.88 0.72 1.06
Cervix 18 1.48 0.88 2.35 15 0.60 0.34 0.99
Endometrium 17 1.13 0.66 1.81 21 0.67 0.42 1.03
Ovary 10 0.70 0.33 1.30 26 0.88 0.58 1.30
Prostate 106 1.24 1.01 1.50 180 1.00 0.86 1.16
Kidney 19 0.92 0.55 1.44 37 0.86 0.60 1.19
Urinary bladder 42 1.49 1.08 2.02 57 0.97 0.74 1.26
Melanoma 19 1.78 1.07 2.79 33 1.53 1.06 2.16
Skin SCC 48 2.72 2.01 3.61 83 2.38 1.89 2.95
Eye melanoma 5 3.26 1.03 7.68 4 1.25 0.32 3.22
Nervous system 9 0.60 0.27 1.14 35 1.13 0.79 1.57
Thyroid gland 6 1.39 0.50 3.04 7 0.78 0.31 1.61
Endocrine glands 10 1.14 0.54 2.10 25 1.40 0.90 2.06
Non-Hodgkin’s lymphoma 16 1.02 0.58 1.67 31 0.96 0.65 1.36
Myeloma 5 0.50 0.16 1.19 27 1.29 0.85 1.88
Leukaemia 15 0.88 0.49 1.45 40 1.11 0.79 1.52
Total 616 1.13 1.04 1.22 1087 0.96 0.90 1.02
aCancer sites with less than five cases are excluded. Bold type: The lower 95% CI does not include 1.00. O, observed; SIR, standardised incidence rate.
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irradiation affects SCC and melanoma in different ways and the
distribution of affected body parts also varies (English et al, 1997).
However, considering the much higher risks from parental SCC
than melanoma, some contribution by ultraviolet radiation to the
SCC–melanoma association is likely. Even more interesting was
the association of invasive SCC (SIR 3.26) with eye melanoma,
constituting some 80% of intraocular tumours, for which sun
ultraviolet radiation has been considered only a weak risk factor
(English et al, 1997). Sweden is located between latitudes 55 and
701, implying that the prevailing low solar altitude causes a
relatively long-lasting ultraviolet radiation exposure of the retina.
A further point is that eye melanoma does not appear to associate
with familial cutaneous melanoma (Sinilnikova et al, 1999;
Hemminki and Jiang, 2001). These data suggest that solar
irradiation is the common denominator for the aggregation of
skin SCC, cutaneous melanoma and ocular melanoma, and this is
supported by recent reports (Shors et al, 2002; Vajdic et al, 2002;
Hemminki et al, 2003). The significance of other associations
between parental prostate and bladder cancers with invasive SCC
remains unclear.
In contrast to the scarcity of familial data on skin SCC, there are
many studies published on second cancers following skin SCC
(Frisch and Melbye, 1995; Levi et al, 1996, 1997, 1998; Wassberg
et al, 1999; Dong and Hemminki, 2001b; Hemminki and Dong,
2000b,c; Milan et al, 2000). These have shown a consistent link
between SCC and melanoma, while an association between skin
and eye cancer has been noted (Milan et al, 2000). Many studies on
second cancers have found an excess of cancers associated with
immunological disturbances and immunosuppression, including
lymphoma, and lip (oral), cervical and connective tissue cancers
(IARC, 1996). However, the present results provide no support for
the role of impaired immune function.
In summary, the present data on relatively young individuals
provided evidence that there is an underlying hereditary sus-
ceptibility explaining at least a part of the familial clustering
of skin SCC. Familial risks between invasive and various in situ
forms of SCC appear to be similar and in many families different
forms of SCC are manifested. The association of skin SCC with
cutaneous and ocular melanoma may be largely because solar
irradiation.
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